Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIMMEL: Radiotherapy and ipilimumab in metastatic melanoma (Phase II)
2015-002058-11Phase 2Terminated
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ipilimumab in melanoma, sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Progression-free survival. Started May 2021; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-002058-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002058-11.